Stay updated on NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial
Sign up to get notified when there's something new on the NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial page.

Latest updates to the NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial page
- CheckyesterdayChange DetectedThe webpage has updated its date references, removing several entries from 2024 and adding new dates in 2025 and 2026.SummaryDifference0.4%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe web page has been updated to reflect a new version of a clinical study on NKTR-214 and nivolumab for high-grade sarcoma, with significant changes in the study's description and collaborators. The previous version's detailed inclusion and exclusion criteria have been removed, indicating a shift in focus towards a more concise overview of the study.SummaryDifference49%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the NKTR-214 Plus Nivolumab in Sarcoma Clinical Trial page.